chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Itching all over; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 19Apr2021 at 12:15 (at the age of 49-year-old) as a single dose for COVID-19 immunisation. Medical history included migraine  and chronic back pain. Prior to the vaccination, the patient was not diagnosed with COVID-19.The patient received unspecified medication within two weeks of vaccination. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 20Apr2021 at 15:45, the patient experienced itching all over. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event itching all over was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Information has been received from an online article via a company representative. The article stated that a doctor said that the incidence of cervical cancer was very low and it was impossible for Merck's Human papillomavirus (HPV) vaccine to lower the already low incidence of cervical cancer. It was reported that the promotion of this vaccine to prevent cervical cancer was entirely groundless, although it was promoted as this. The study confirmed that the indication of this vaccine had nothing to do with cervical cancer, however, the way of promotion still ignored this fact. In fact, there was no evidence to support that this vaccine could prevent any cancer. According to Merck's labeling, this vaccine (the 1st generation) targeted four types of all the 40 types of HPV, which could be self-healing in short time. The article also concerned about the potential risks of this vaccine, as it indicated all the clinical trials were conducted among the females aged 15-year old or above, however, Food and Drug Administration (FDA) and Merck had extended the target users to girls of 9-year old and above, even boys. It was reported that so far there had been 15,037 cases of adverse drug reaction for this vaccine, and the statistics only included cases that met the very stringent validation criteria. There had been 44 girls that were confirmed to die of this vaccine (captured in MARRS#1609USA013709). All kinds of adverse drug reactions included Guillain-Barre syndrome (paralysis), lupus erythematous, thrombus and encephalitis (Cerebral palsy). This report refers to unspecified number of patients who experienced Guillain-Barre syndrome (paralysis), lupus erythematous, thrombus and encephalitis (Cerebral palsy). Upon internal review, the adverse events were considered to be medically significant. Additional information has been requested.
Information has been received from a registered nurse concerning a 13 year old female with a history of recent foreign travel and no known drug allergies who on 11/06/2002 was vaccinated with a dose of medication.  On 11/07/2002, the child developed jaundice and diarrhea.  On 11/18/2002 a positive diagnosis of hepatitis "A" was made based on serologic testing.  On 11/25/2002 it was reported that there was a possible vaccine failure.  Unspecified medical attention was sought.  Additional information has been requested.
Pt recv vax on 2/3/99; on 2/4/99 pt exp warm, red streak at right thigh vax site; tx=warm packs & Tylenol
2 days fever - 101 degrees, aches in joints similar to flu with headache. 3 weeks after injection blood vessels burst in left arm leaving lower arm/wrist with very large bruise or venous flood.
Loss of speech, temper tantrums, loss of toilet skills and behavior problems. Treatment: Lovaas, Speech, AIT Therapy, occupational therapy. The 60 day follow-up states loss of speech, loss of toilet skills, learning disabilities, loss of social skills, temper tantrums, repetitive behaviors. "We truly believe the vaccinations that our daughter received caused her autism because she was developing normally until this." An annual follow up report received 07/31/2003 adds: Recipient was normal up until age 2, when she became autistic (loss of speech, toilet skills, social skills, etc.) and is still autistic today.
Systemic: Chest Tightness / Heaviness / Pain-Mild, Systemic: Exhaustion / Lethargy-Medium, Systemic: Fever-Mild, Systemic: Joint Pain-Mild
Fever : 101-102 F x 3 days (starting same evening as vaccination); Mild diarrhea, occasional vomitting x 3 days; Localized redness & swelling x 3 days- Local ice packs, motrin as needed & benadryl as needed
This information has been received from a medical assistant concerning an unspecified number of patients of unknown age and gender. The patients' medical history, drug allergies, concurrent conditions and concomitant therapies were not reported. Between 10-MAY-2017 and 16-MAY-2017, the patients were vaccinated with improperly stored doses of VARIVAX with lot number M019641 and expiration date on 20-APR-2018 (dose, dose number, route of administration and anatomical location were not provided), administered for prophylaxis. It was reported that on an unspecified date, the vaccine was exposed to a temperature between 47 Fahrenheit degrees and 77 Fahrenheit degrees for 90 minutes. There was no previous temperature excursion. The call was placed because of a Digital Data logger report. No product quality complained was involved. No adverse effects were reported. This is one of several reports received from the same source.  Additional information has been requested.; Sender's Comments:  US-009507513-1705USA014918: US-009507513-1705USA014919:
Upon arrival subject is CAOx4. Subject is found sitting in her car, after receive her COVID vaccine. Subject stated that she would like to be checked out. Subject stated that she does not having any symptoms, but would like to double check everything is okay. Subject's skin warm/dry, respiratory rate/ effort normal, pulse rate fast/regular, mucous membrane pink/dry. EMS note subject's Spo2 is in the upper 90's, subject Is noted to be tachycardic. Subject stated that she normally has a fast heart rate when she is getting an examination done. Rhythm showed Sinus Tachycardia with no significant ST elevation. Subject stated that she feels fine. Subject denied any shortness of breath, chest pain, blurry vision, headache, N/V/D. EMS monitored the subject for a moment to see if heart rate would come down. After approximately 10 minutes EMS not that subject's heart started to come down. EMS offer transport to the hospital to the subject. Subject stated that she feels okay and does not wish to go to the hospital. EMS explains the risk of not being further evaluated. Subject stated that she understands and does not wish to go to the hospital.
Chills, body aches, pounding headache, fatigue,  cognitive changes. Lasted 8 hours.
Began to have headaches; Muscles began to feel weak; Chills throughout body; A fever overnight; Left arm is beginning to swell up and that is the arm that received the shot on; This is a spontaneous report from a non-contactable consumer, the patient. A 20-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Aug2021 at 13:15 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. Medical history included no allergies but mainly environmental allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Aug2021 at 21:30, one week after receiving the vaccine, the patient began to have headaches and muscles began to feel weak. He got chills throughout the body and a fever overnight. His left arm was beginning to swell up and that was the arm which had received the shot. The events did not result in a visit to doctor or other healthcare professional office/clinic, and emergency room/department or urgent care.  Therapeutic measures were taken as a result of events which included treatment with over the counter medicine like naproxen sodium (FLANAX). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events began to have headaches and muscles began to feel weak, got chills throughout the body and a fever overnight and the left arm was beginning to swell up and that was the arm which had received the shot were not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous case was reported by a consumer and describes the occurrence of TREMOR (shaking), INFLUENZA LIKE ILLNESS (had flu-like symptoms), FEELING ABNORMAL (it laid me out) and CHILLS (shivering) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Concurrent medical conditions included High cholesterol. In November 2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In November 2020, the patient experienced TREMOR (shaking), INFLUENZA LIKE ILLNESS (had flu-like symptoms), FEELING ABNORMAL (it laid me out) and CHILLS (shivering). At the time of the report, TREMOR (shaking), INFLUENZA LIKE ILLNESS (had flu-like symptoms), FEELING ABNORMAL (it laid me out) and CHILLS (shivering) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: high cholesterol (High) had blood work done. Everything shows up normal. It did show high cholesterol. mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged. No concomitant product use was reported. Patient had experienced all symptoms on the same day of vaccination. It was also reported that the patient had seen doctors and they said there were no conditions. No treatment information was provided. This case was linked to MOD-2022-513826, MOD-2022-513827 (Patient Link).
Patient received immunization and was talking to vaccine administrator when she fainted and fell to floor unconscious for one to two minutes. Pt. regained consciousness and continued to lie prone. Called husband and she left under own power. Saw today. No further complaint of problems.
Fever Headache Tiredness Cough Throat pain Rash (in the area of ??application Redness (in the area of ??application) Inflammation (in the area of ??application) Pain (in the area of ??application) And it is hot (in the application area).
R arm pain "as if someone socked me in the arm" at injection site; chills/shaking "as if my internals are trying to come out"; chills/shaking "as if my internals are trying to come out"; Headache; This is a spontaneous report from a non-contactable other healthcare professional. A 52-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on an unknown date (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received varicella zoster vaccine (MANUFACTURER UNKNOWN) via an unspecified route of administration on an unknown date for an unknown indication and experienced adverse reaction, unable to recall what to the chicken pox vaccine. She had only been able to get one shot. She had tolerated other vaccines without issues. On an unknown date, during her 30 minutes waiting period after the injection, the patient began to experience chills/shaking "as if her internals were trying to come out". She also reported of right (R) arm pain "as if someone socked me in the arm" at the injection site. Therapeutic measures were taken as a result of the events she also reports of R arm pain "as if someone socked me in the arm" at injection site, during her 30-minute waiting period after the injection, the patient began to experience chills/shaking "as if her internals are trying to come out" included treatment with water, snacks and ibuprofen (MANUFACTURER UNKNOWN) for headache. The reporter stated follow up response to treatment was excellent. The patient was stable to go home and follow up with PCP. The clinical outcome of the event she also reports of R arm pain "as if someone socked me in the arm" at injection site, during her 30-minute waiting period after the injection, the patient began to experience chills/shaking "as if her internals are trying to come out" and headache was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.  Amendment: This follow-up report is being submitted to amend previously reported information: Updated Historical vaccine reaction Coding "Adverse drug reaction NOS" to "Adverse event nos", removed onset latency for all events.
screaming lasting 4 hrs @ very high pitch; MD was called pt could not be comforted for the entire 4 hrs;
Hives that move to different parts of body. Worse with warm shower or itching. Antihistamines help. Slightly better but still present two weeks later. Only got hives after booster
In addition to my neck continuing to hurt since 1st vaccine, I now have ear pain in my left ear that stated 5 days after second dose.
8x6 cm erythematous lesion on the injection site. No pain. No fever. No itch. Recovered in 3 days.
fluid build up in lungs; Guillain-Barre syndrome; This is a spontaneous report from a contactable consumer (patient).   A 78-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration on 19Mar2021 15:30 (Lot Number: ERZ2613) at the age of 78-year-old as single dose for covid-19 immunisation. The patient's medical history was not reported. The patient had no COVID prior vaccination and had no allergies. The patient has other medication (unspecified) in two weeks. The patient previously took the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number=EN6202) on 26Feb2021 15:30 PM at the age of 78-year-old for covid-19 immunisation and experienced low energy, loss appetite & weakness 3 weeks after initial injection, although no pain in arm. In Mar2021, within the first week of the second shot, he was admitted to the hospital with fluid build up in the lungs. Within two weeks of his second injection he was diagnosed with Guillain-Barre syndrome. These events resulted in emergency room/department or urgent care, hospitalization, disability or permanent damage. The patient was in hospitalization for 12 days. The patient had COVID test type post vaccination: Nasal Swab with unknown results in 2021. The patient received plasma exchange for events. Outcome of events was recovering.    Follow-up attempts are completed. No further information is expected.
Systemic: Chills-Mild, Systemic: Confusion-Mild, Systemic: Dizziness / Lightheadness-Mild, Systemic: Fever-Mild, Systemic: Flushed / Sweating-Mild, Systemic: Hypotension-Mild, Systemic: Nausea-Mild, Systemic: Visual Changes/Disturbances-Mild
After receiving my vaccine I had a sore left arm. fatigue, headache an entire day.
ON 2/24/09, AN MMR AND A VARIVAX WERE ADMINISTERED TO THIS PATIENT BY THE OFFICE MEDICAL ASSISTANT. ON MARCH 10, MOM CALLED AND STATED THAT THE CHILD HAD A DRY NASAL DISCHARGE AND A RASH ON HER FACE "LIKE BROKEN BLOOD VESSELS". OUR TRIAGE NURSE GAVE CHILD AN APPT FOR THE SAME DAY WITH HER PCP. DAD BROUGHT CHILD IN AND STATED CHILD HAD BLOODY MUCUS IN THE NOSE AND RED SPOTS ALL OVER HER BODY WHICH DR. DIAGNOSED AS PETICHIAE. DR.ORDERED BLOOD WORK AND IT WAS DISCOVERED THAT HER PLATELET COUNT WAS 6,000. HE HAD THE CHILD SEE A PEDIATRIC HEMATOLOGIST ON THE SAME DAY AND DR. ADMITTED THE CHILD INTO MEDICAL CENTER ON MARCH 10, 2009 WITH A DIAGNOSIS OF ITP. SHE WAS TREATED WITH INTERVENOUS IMMUNOGLOBULINS. SHE WAS DISCHARGED HOME IN STABLE CONDITION ON MARCH 12, 2009.  5/4/09 Received hospital medical records of 3/11-3/12/2009. FINAL DX: idiopathic thrombocytopenia purpura Records reveal patient experienced injection site bruising, nosebleed, irritability, decreased appetite, purple spots on lips & cheek then developed petechiae all over body.  Saw PCP who did labs & plt ct of 6.  Referred to Heme clinic who admitted. Tx w/IVIG & plt ct increased to 36.  D/C to home w/Heme clinic f/u for serial labs.
Patients were mentally delayed brothers with similar names and they told me the wrong name. The patient's mother stated that they do this all the time and she apologized for not catching it. Patient received an HPV vaccine that his brother should have received. They both also received tetanus and flu vaccines.
administered in 17May2022, expiration date of 01May2022; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 2-month-old female patient who received Rota (Rotarix lyophilized formulation) (batch number 5994B, expiry date 1st May 2022) for prophylaxis.   Co-suspect products included rotavirus vaccine oral applicator device (Rotarix Oral Applicator Device) oral applicator for prophylaxis.   On 17th May 2022, the patient received the 1st dose of Rotarix lyophilized formulation and Rotarix Oral Applicator Device. On 17th May 2022, unknown after receiving Rotarix lyophilized formulation and Rotarix Oral Applicator Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date:17-May-2022 Reporter's comments: Clinical Supervisor reported that the patient received expired Rotarix. At the time of reporting, the dose has not been repeated. The reporter gave permission for follow-up. Additional Supportive Information: The patient received expired dose of Rotarix, which led to expired vaccine used.
Saturday evening, I started experiencing confusion and slight chills. On Sunday, I had extreme chills and a fever of 100.3-degrees. That lasted until about 03:00AM on Monday morning. During that whole period, I had extreme confusion and felt lethargic. I also had muscle pain and fatigue. Tuesday, I returned to work as my fever was gone. The confusion and slowness were evident by everyone around me. It continued throughout the day. By the end of the day, my coworkers were concerned as my speech was slurred. They drove me home because they didn't trust my driving. When I got home, my wife noticed my lips and hands were blue, but my face was pale. We checked my blood pressure. It was 176/96. I called the pharmacy where I received the vaccine. The Pharmacist said to continue to monitor my blood pressure and said to go to the hospital if it crested 180 to avoid organ damage. Later that night, the fever and chills returned. The fever was 101.6-degrees. The fever broke about four or five hours later. On February 1, 2023, I scheduled an appointment with my doctor and saw him the same day. They took blood and administered a Flu test and a COVID-19 test. Later that night, they called to let me know the test results were negative and the blood work showed no signs of infection.
Janssen COVID-19 Vaccine EAU Sore arm, headache, body aches, chills, and fatigue, mostly from 10pm and on through the night.  Symptoms subsided within 24 hours of injection.
still have shoulder pain two days after moderna vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of ARTHRALGIA (still have shoulder pain two days after moderna vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (still have shoulder pain two days after moderna vaccine). At the time of the report, ARTHRALGIA (still have shoulder pain two days after moderna vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment and concomitant medicines were reported
received covid 19 vaccine 12 min prior to arrival        felt palpitations, dizzy         ate prior to arrival         no known history of allergic or adverse vaccine reactions        no chest pain, SOB, tongue/lip/throat swelling, vomiting, diarrhea, abd pain        remaining ROS neg Symptoms resolved after approximately 5 minutes
15:33 Client received Tri-Influenza vaccine 0.5ml administered via R deltoid within 10 min visualized edematous hives localized to face and R posterior arm breathing/respiration regular rate and rhythm, client denied any other symptoms, referred to ER for further eval. B/P 102 64 P 112.
This patient had Bell's Palsy onset 2 days after his immunization. No specific treatment other than natural tears and toning of affected eye. Bell's Palsy resolved by 04/21/2001
After my second shot of Shingrix  I experienced severe Rheumatoid arthritis:  Swelling  and in hands, wrists and elbows, making it hard to dress, put on shoes or brush teeth . Swelling and pain in my feet making walking on a wood flor painful Swelling  and pain in my knees making walking, stair, biking and all functions difficult. Even SITTING for prolonged periods of time creates more pain
Hypertensive emergency. ED visit and hospitalization. This visit was within 6 weeks of receiving the COVID vaccine.
Patient fully vaccinated and boosted with Pfizer on 4/20/21, 5/11/21, and 3/1/22. Patient has a history of type 1 diabetes and ESRD. Presented to ED on 3/3/22 with complaints of shortness of breath. Previously hospitalized for over one month in January for acute respiratory distress requiring intubation and trach. Patient was admitted for DKA on 3/4/22 and discharged on 3/12/22.
Developed itchy rash the day after receiving 2 vaccines. Rash persisted for one week without improvement from oral BENADRYL. Came to a walk-in retail clinic for evaluation of the rash Diagnosis urticaria with angioedema or anaphylaxis.
Information was received from a nurse, referring to a 22 year old non-pregnant female patient. The patient did not have concomitant medication, medical history and drug reactions/allergies. On 15-FEB-2017, the patient was vaccinated with her first dose of GARDASIL 9 (lot# was reported as L012190 with expiration date 13-APR-2017; concentration, frequency and route were unknown) for vaccination. Since 15-FEB-2017 to 27-FEB-2017, the patient experienced headache. No lab diagnostics study was performed, and no treatment was given for the event. At the time of reporting, the patient was not recovered from the event. The causality between headache and GARDASIL 9 was not provided. No product quality complaint was involved. Lot number L012190 is an invalid lot number for hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast). Additional information has been requested.